Want to see HK:2348 full AI Analyst Report?
Dawnrays Pharmaceutical Holdings Ltd. (2348) AI Stock Analysis
Dawnrays Pharmaceutical Holdings Ltd.
(HKEX:2348)
The score is driven primarily by solid financial standing (notably very low leverage and healthy margins) and strong valuation support (low P/E and high dividend yield). This is tempered by inconsistent earnings/revenue stability and a neutral-to-weak technical trend with negative MACD and price below key longer-term moving averages.
Dawnrays Pharmaceutical Holdings Ltd. (2348) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.39B
- Dividend Yield
- 6.85%
- Average Volume (3M)
- 333.02K
- Price to Earnings (P/E)
- 5.1
- Beta (1Y)
- 0.27
- Revenue Growth
- 6.55%
- EPS Growth
- 36.62%
- Country
- Hong Kong
- Employees
- 1,074
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Dawnrays Pharmaceutical Holdings Ltd. Business Overview & Revenue Model
Company Description
Dawnrays Pharmaceutical (Holdings) Limited operates as an investment holding company, primarily engaged in the creation, production, and global distribution of generic pharmaceutical medicines, with a focus on Mainland China and international markets...
How the Company Makes Money
null
Dawnrays Pharmaceutical Holdings Ltd. Financial Statement Overview
Summary
Strong balance sheet (very low leverage) and generally healthy margins support the score, while uneven revenue trends and a sharp decline in 2025 net income versus 2024, plus historically variable cash conversion, limit it.
Income Statement
64PositiveBalance Sheet
86Very PositiveCash Flow
68Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.14B | 1.23B | 1.06B | 1.15B | 1.28B | 1.17B |
| Gross Profit | 544.47M | 557.40M | 577.63M | 641.52M | 766.68M | 675.36M |
| EBITDA | 361.10M | 347.57M | 308.67M | 498.94M | 505.19M | 438.31M |
| Net Income | 231.04M | 213.97M | 564.94M | 326.00M | 358.06M | 358.18M |
Balance Sheet | ||||||
| Total Assets | 3.99B | 4.01B | 4.01B | 3.62B | 3.67B | 3.34B |
| Cash, Cash Equivalents and Short-Term Investments | 1.59B | 1.58B | 1.37B | 1.07B | 993.04M | 830.22M |
| Total Debt | 4.48M | 77.51M | 34.72M | 120.53M | 8.41M | 23.52M |
| Total Liabilities | 552.42M | 621.75M | 682.61M | 763.42M | 1.02B | 941.70M |
| Stockholders Equity | 3.43B | 3.39B | 3.32B | 2.85B | 2.64B | 2.38B |
Cash Flow | ||||||
| Free Cash Flow | 298.09M | 236.01M | 44.58M | 126.39M | 229.90M | 80.07M |
| Operating Cash Flow | 376.95M | 355.41M | 220.20M | 338.40M | 434.27M | 393.14M |
| Investing Cash Flow | -237.08M | -368.80M | 205.17M | -387.57M | -175.01M | -284.20M |
| Financing Cash Flow | -64.19M | -54.99M | -189.44M | 2.07M | -92.70M | -129.75M |
Dawnrays Pharmaceutical Holdings Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2348, the sentiment is Negative. The current price of 0.92 is below the 20-day moving average (MA) of 0.95, below the 50-day MA of 0.97, and below the 200-day MA of 1.03, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 39.48 is Neutral, neither overbought nor oversold. The STOCH value of 20.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2348.
Dawnrays Pharmaceutical Holdings Ltd. Peers Comparison
Overall Rating
- HK:234875Outperform
HK:216173Outperform
HK:263370Outperform
HK:095068Neutral
HK:256142Neutral
HK:165241.5Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2348 | 75Outperform | HKD 1.39B | 5.12 | 6.78% | 6.85% | 6.55% | 36.62% |
| HK:2161 | 73Outperform | HKD 1.36B | 6.64 | 18.70% | 10.30% | 6.69% | 2.45% |
| HK:2633 | 70Outperform | HKD 1.78B | 6.19 | 13.26% | 9.67% | -0.47% | -0.40% |
| HK:0950 | 68Neutral | HKD 606.50M | 3.64 | 8.02% | 5.61% | 7.05% | 22.46% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2561 | 42Neutral | HKD 1.59B | -5.37 | -33.42% | ― | ― | ― |
| HK:1652 | 42Neutral | HKD 757.28M | -273.12 | -0.66% | ― | 18.14% | 98.32% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2348 | Dawnrays Pharmaceutical Holdings Ltd. | 0.92 | -0.20 | -17.86% | |
| HK:0950 | Lee's Pharmaceutical Holdings Limited | 1.03 | -0.77 | -42.94% | |
| HK:1652 | Fusen Pharmaceutical Co., Ltd. | 1.03 | 0.21 | 25.61% | |
| HK:2161 | JBM (Healthcare) Ltd. | 1.66 | -1.11 | -40.09% | |
| HK:2633 | Jacobson Pharma Corporation Limited | 0.94 | -0.42 | -30.74% | |
| HK:2561 | VISEN Pharmaceuticals | 13.93 | -24.67 | -63.91% |
Dawnrays Pharmaceutical Holdings Ltd. Corporate Events
Dawnrays Pharmaceutical Grants 10 Million Share Options to Staff Under 2023 Scheme
Dawnrays Pharmaceutical has granted 10 million share options under its 2023 Share Option Scheme to 14 eligible employees of the group, with an exercise price of HK$1.00 per share and a six-year validity period. The options vest in five equal annual t...
Dawnrays Commits RMB100 Million to New Biopharmaceutical Venture Fund
Dawnrays Pharmaceutical’s wholly owned unit Suzhou Dawnrays has agreed to form a biopharmaceutical venture capital investment fund partnership with Zhongjianxin and Shanghai Jianxin, committing up to RMB100 million for a 50% stake in the fund&#...
Dawnrays Wins China Approval for New Antidepressant Tablets
Dawnrays Pharmaceutical has reported that its subsidiary, Fujian Dawnrays Pharmaceutical, has received Chinese regulatory approval to produce and register 50mg and 100mg Trazodone Hydrochloride tablets, classified as a type 3 chemical drug that has p...
Dawnrays Wins China Nod for Once‑Weekly Diabetes Drug
Dawnrays Pharmaceutical’s subsidiary Suzhou Dawnrays Pharmaceutical Co., Ltd. has secured Chinese regulatory approval to produce and market Trelagliptin Succinate Tablets in 50mg and 100mg strengths, classified as a type 3 chemical drug that ha...
Dawnrays Pharmaceutical Wins Full Shareholder Backing at 2026 AGM
Dawnrays Pharmaceutical (Holdings) Limited reported that all resolutions at its 22 May 2026 annual general meeting were approved by shareholders via poll, with nearly all votes cast in favour. Directors, barring one absent for overseas work commitmen...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 04, 2026